Nektar Therapeutics Successfully Completes $373.8 Million Public Offering of Shares

Nektar Therapeutics Closes a Major Public Offering

Nektar Therapeutics, a leading clinical-stage biotechnology firm specialized in pioneering immunology treatments, has successfully closed its latest public offering, raising an impressive $373.8 million. The company sold 4,062,500 shares of common stock, with an additional 529,891 shares sold following the full exercise of the underwriters' option. Shares were priced at $92.00 each, enabling Nektar to secure significant gross proceeds for its innovative pipeline.

The completion of this offering is viewed as a strategic move to further advance Nektar's research and development of novel therapies for various immune-related ailments. Nektar’s lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), represents a pioneering class of regulatory T cell stimulators currently under evaluation in multiple clinical trials for conditions such as atopic dermatitis, alopecia areata, and Type 1 diabetes mellitus.

Acting as joint bookrunning managers for this noteworthy offering were Jefferies, TD Cowen, and Piper Sandler, while Citigroup also played a crucial role as a bookrunner. This public offering was enacted under a shelf registration statement filed with the U.S. Securities and Exchange Commission (SEC) on November 12, 2025, signaling the company’s forward-thinking approach to financing its growth.

Nektar's decision to engage in this substantial financing demonstrates confidence in their ongoing projects and the potential to transform the treatment landscape for autoimmune disorders. The influx of capital will support crucial clinical trials and the advancement of other promising therapies in their pipeline, including preclinical assets focused on therapeutic antibodies and modified proteins.

With a solid foundation built on scientific innovation and targeted therapeutic strategies, Nektar is well-positioned to lead the charge in addressing the unmet needs of patients suffering from complex immunological conditions. The company’s focus on developing therapies that correct the root cause of immune dysfunction sets it apart in the biotechnology landscape.

For investors and stakeholders, the final prospectus supplement detailing the terms related to this offering is accessible on the SEC's website. Copies can also be requested from the joint bookrunning managers directly.

As Nektar moves forward, this funding ensures essential support for their research objectives and solidifies their position as a frontrunner in the biotechnology sector, driven by a commitment to improve patient outcomes in autoimmune diseases. The strategic financial maneuver not only enhances their operating capabilities but also serves as a robust endorsement of their clinical programs, paving the way for future innovations in immunological therapies.

As the landscape of medicine continues to evolve, companies like Nektar Therapeutics are at the forefront, pushing boundaries, and working diligently to bring to market groundbreaking solutions to improve health and well-being. The future looks promising as they forge ahead, empowered by this significant financial backing.